|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.14 / 0.55|
Trade-Ideas LLC identified iBio (IBIO) as a pre-market mover with heavy volume candidate
Shares of iBio (IBIO) were soaring in morning trading Monday after a nurse in Texas was diagnosed with the Ebola virus, which deepened concerns about an outbreak in the U.S.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Stocks that are making large moves are favorites among short-term traders because they can try to capture some of that massive volatility.
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin.
iBio, Inc. (NYSE AMEX: IBIO) today announced successful animal testing of a malaria vaccine candidate produced using its proprietary iBioLaunch™ platform and sponsored by the Bill & Melinda Gates Foundation.
TheStreet Ratings released initial ratings on 10 U.S. common stocks in July. Two of these stocks start out at 'sell' and eight earned a recommendation of 'hold' from our stock model.
iBio, Inc. (NYSE AMEX: IBIO) today announced successful production of human plasma proteins using its proprietary iBioLaunch technology.
iBio, Inc. (NYSE AMEX:IBIO), a leader in new transient expression technologies for the development and production of biologics using plants, today announced that it has been added to the Russell Microcap Index,...
iBio, Inc. (NYSE AMEX: IBIO) announced today the appointment of Jules A.
iBio, Inc. (NYSE AMEX: IBIO) announced that an open house for sell-side analysts and institutional fund managers will be held on June 16, 2011, at its Newark, Delaware headquarters, commencing at 10:00 A.
iBio, Inc. (NYSE AMEX: IBIO) today announced positive interim results from a Phase 1 clinical trial of an iBioLaunch™ platform-produced subunit vaccine directed against Influenza A/California/04/09 (H1N1).
iBio, Inc. (NYSE AMEX: IBIO) today announced that members of the Company’s senior management will present at the Wells Fargo Securities Healthcare Conference on Thursday, June 23rd, at 11:15 a.
iBio, Inc. (NYSE AMEX: IBIO) today announced that its proprietary iBioLaunch™ Platform successfully expressed the hookworm-derived molecule known as NaAPR1M-74, which will be evaluated as a potential vaccine...
iBio, Inc. (NYSE AMEX: IBIO), the company commercializing the iBioLaunch™ Platform for vaccines and biotherapeutics, announced that its president, Mr.
iBio, Inc. (NYSE AMEX: IBIO) today announced the engagement of CBR International Corporation (CBR) for strategic regulatory and clinical services to advance iBio’s Orphan Drug designated, plant-produced human...
iBio, Inc. (NYSE AMEX:IBIO) announced today that Douglas Beck, C.
iBio, Inc. (NYSE AMEX: IBIO) today announced release of results from a series of scientific studies of the breadth of product applicability of its iBioLaunch™ technology.
iBio, Inc. (NYSE AMEX:IBIO) today announced that Terence E.
iBio, Inc. (NYSE AMEX:IBIO) today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A (“α-Gal A”) and related property rights from an affiliate of Kentucky ...
iBio, Inc. (NYSE AMEX:IBIO) today announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon iBio’s proprietary...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.